Core Lecture Series Flashcards
Describe the image

RAO Caudal
- LAD (on top)
- CFx (coming towards front)

Describe the image

LAO Cranial

Describe the findings


Describe the findings

LAO Straight

Describe the findings

LAO Cranial

Describe the findings

RAO Straight

What are the branches of the SMA?
- inferior pancreaticoduodenal
- intestinal
- ileocolic
- right colic
- middle colic
What are the branches of the celiac trunk?
- Left gastric
- Common hepatic
- Splenic
Describe the views and imaging of the left coronary system

Describe the image


Describe the image


Describe the image


Describe the image


Describe the image


Describe the image


Describe the image


Describe the views and imaging of the right coronary system

Describe the image


Describe the image


Describe the image


Describe the findings of the LV gram


What is the most common challenge in regards to radial access?
vasospasm
What tests should be performed before attempting radial access?
Why?
- Barbeau or Allen’s Test
- To assess ulnar and radial flow in the superficial palmar arch
What is the best treatment for radial artery vasospasm during cath?
- Intra-arterial vasodilators
- verapamil, Nitrates
- Sedation
- Minimizing catheter manipulation and catheter exchanges
What is a dreaded complication or transradial access?
compartment syndrome
What is one way to treat suspected compartment syndrome related to cardiac catheterization?
early recognition and tamponade
- often using a sphygmomanometer cuff to apply direct pressure to the forearm
What percentage of patients following transradial access will develop arterial thrombosis?
up to 10%
What is the optimal projection for visualizing:
- LMCA
- Proximal and mid-LM
- RAO caudal (shallow)
- AP caudal
- Distal LM
- LAO Caudal
What is the optimal projection for visualizing:
- LAD
- Proximal
- LAO caudal
- LAO cranial (if foreshetening occurs with LAO caudal)
- RAO cranial
- eliminates foreshortening seen with LAO cranial/caudal views but overlap with CFx may occur in proximal LAD
- Mid
- AP cranial or
- RAO cranial
What is the optimal projection for visualizing:
- CFx
- AP caudal
- LAO caudal (shallow)
- RAO caudal
- Proximal
- RAO caudal (shallow)
- may be compromised by foreshortening
- RAO caudal (shallow)
- Ostium of RI
- LAO caudal (steep)
What is the optimal projection for visualizing:
- RCA
- Proximal
- LAO straight
- Mid
- left lateral projection
- Distal RCA, PDA, PLB bifuraction
- LAO cranial
- Proximal and mid PDA
- RAO
What is the optimal projection for visualizing:
- LIMA
Lateral projection
What study demonstrated the noninferiority of Edoxaban over Warfarin in nonvalvular A-fib?
Engage AF-TIMI 48
- Primary Outcome - systemic or embolic event (Modified intention to treat) - p < 0.001
- Warfarin - 1.5% / year
- High dose (60mg) - 1.18% / year
- Los dose (30mg) - 1.61% / year
- Major Bleeding - p < 0.001
- Warfarin - 3.43% / year
- High dose (60mg) - 2.75% / year
- Los dose (30mg) - 1.61% / year
What did the RE-VERSE AD trial show?
- Clinical Question
- Among patients receiving dabigatran who develop serious bleeding or need an urgent invasive procedure, does idarucizumab reverse the anticoagulatnt effects of dabigatran?
- Bottom Line
- Among patients receiving dabigatran who develop serious bleedin or need an urgent invasive procedure, idarucizumab reverses the anticoagulant effects of dabigatran within minutes of administration
What is the reversal agent for Dabigatran?
Idarucizumab (Praxbind)
- monoclonal antibody fragment that binds dabigatran
- rapidly normalizes hemostasis and reduces levels of circulating dabigatran in patients who had serious bleeding or required urgent procedure (RE-VERSE AD)
- Class I recommendation
What is the reversal agent for Rivaroxaban and Apixaban?
Andexanet alfa (Andexxa)
- coagulation factor Xa [recombinant], inactivated-zhzo
- bioengineered, recombinant modified protein designed to serve as an antidote against direct factor Xa inhibitors
*
Which NOAC is able to be removed with Hemodialysis?
Dabigatran
What did the AFFIRM trial show?
- Clinical Question:
- Among patients with A-fib and a high risk of stroke or death, what are the effects of rate control versus rhythm control on mortality?
- Bottom Line:
- In patients with nonvalvular AF, there is no survival benefit between rate and rhythm control, but rhythm trends toward increased mortality
What were the AFFIRM study outcomes:
- Primary
5 year mortality
- Rate control - 25.9%
- Rhythm control - 26.7%
- P = 0.08
What were the AFFIRM study outcomes:
- Secondary (notable)
-
Hospitalization:
- 73% vs. 80% - p < 0.001
-
Ischemic strokes
-
5.5% vs. 7.1% (p = 0.79)
- mostly in patients whom warfarin had been stopped or INR subtherapeutic
-
5.5% vs. 7.1% (p = 0.79)
-
Torsades, PEA, Bradycardia
- all in favor of rate control
Which NOAC has the greatest degree of renal excretion?
Dabigatran (Pradaxa)
- 80% renal excretion
What is the recommended dose reduction for Apixaban (Eliquis)?
Dose?
- Age > 80 years
- Body weight < 60 kg
- Serum Cr > 1.5 mg/dl
- 2.5mg BID
What is the recommended dose reduction for Rivaroxaban in renal impairment?
Renal function cutoff?
- Rivaroxaban 15mg daily
- CrCl 15-50 ml/min
What is the mechanism of action of edoxaban?
factor Xa inhibitor
What is the recommended renal function cutoff/dose reduction for Edoxaban?
- CrCl 51-95 mL/min –> 60 mg daily
- CrCl 15-50 mL/min –> 30mg daily
- CrCl < 15 or > 95 mL/min –> not recommended
Define supraventricular tachycardia (SVT)
arrhythmia that requires the nonventricular cardiac tissues for maintenance of tachycardia
What are the most common SVT’s?
- AVNRT (60%)
- AVRT (30%)
- AT (10%)
What is the best way to differentiate:
- regular, narrow complex tachycardia
-
Long RP (RP > PR)
- Sinus tachycardia
- Atrial tachycardia
-
Short RP (RP < PR)
- AVNRT
- AVRT (Accessory pathway)
What is the best way to dist
What clinical features can help distinguish between SVT’s?
character of symptom onset
- AVNRT or AVRT
- sudden, abrupt onset and termination without any clear inciting factor
- AT
- gradual onset and resolution
- possible trigger (such as exercise)